FDA PMA FDA Class 2 30-Day Notice Accepted 🇺🇸 United States

Assay, Hybridization And/Or Nucleic Acid Amplification For Detection Of Hepatitis C Rna,Hepatitis C Virus

PMA: P060030 · Supplement: S065 · Decision Jul 3, 2018
Classifications
1
FEI Numbers
10
Registration Numbers
10

Basic Information

Device Name
Assay, Hybridization And/Or Nucleic Acid Amplification For Detection Of Hepatitis C Rna,Hepatitis C Virus
Trade Name
COBAS TaqMan HCV Test, v2.0, For use with the High Pure System, High Pure System Viral Nucleic Acid Kit
PMA Number
P060030
Supplement Number
S065
Device Class
FDA Class 2
Product Code
MZP
Generic Name
Assay, hybridization and/or nucleic acid amplification for detection of hepatitis c rna,hepatitis c virus
Regulation Number
866.3170
Medical Specialty
Microbiology
Advisory Committee
Microbiology
Decision
30-Day Notice Accepted
Decision Code
OK30
Decision Date
July 3, 2018
Date Received
June 4, 2018
Supplement Type
30-Day Notice
Supplement Reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Expedited Review
N

Advisory Committee Statement

Reduce Environmental Monitoring testing at a manufacturing facility.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
MZP Assay, Hybridization And/Or Nucleic Acid Amplification For Detection Of Hepatitis C Rna,Hepatitis C Virus